UPB - NASDAQ

Upstream Bio, Inc.

UPB·NASDAQ

$20.97

-5.9%

HealthcareBiotechnology

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.13B

EPS-0.7400

P/E Ratio-3.69

Earnings Date11/06/2025

upb

Property, Plant, and Equipment (Net)

Last Annual Value

2.37M

3-Year CAGR

143%

5-Year CAGR

71%

10-Year CAGR

31%

Adjust for Inflation

Upstream Bio, Inc. Competitors Analysis of Property, Plant, and Equipment (Net)

UPB · NASDAQ

Company	Property, Plant, and Equipment (Net)	CAGR 3Y	CAGR 5Y	CAGR 10Y
Upstream Bio, Inc. NASDAQ:UPB	2.37M	127.1%	N/A	N/A
Dianthus Therapeutics, Inc. NASDAQ:DNTH	1.63M	26.9%	-26.2%	12.4%
Praxis Precision Medicines, Inc. NASDAQ:PRAX	239.00K	-55.2%	-45.3%	N/A
Prime Medicine, Inc. NASDAQ:PRME	146.75M	58.9%	56.4%	N/A
Relay Therapeutics, Inc. NASDAQ:RLAY	41.72M	-15.4%	8.8%	N/A
Septerna, Inc. NASDAQ:SEPN	25.93M	14.7%	N/A	N/A
Zenas BioPharma, Inc. NASDAQ:ZBIO	1.39M	11.0%	N/A	N/A
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	2.03M	35.6%	N/A	N/A
Nektar Therapeutics NASDAQ:NKTR	5.00M	-48.6%	-51.0%	-22.7%
Phathom Pharmaceuticals, Inc. NASDAQ:PHAT	3.67M	0.4%	7.4%	N/A

Upstream Bio, Inc. Fair Value Envelope

UPB · NASDAQ

Our analysis suggests that UPB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $20.97, this represents a potential HIDDEN relative to our calculated worth for Upstream Bio, Inc..

HIDDEN

Intrinsic Value

Current Price: $20.97

Related Guides

Blog Categories

Continue your UPB research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.